Works matching IS 11738804 AND DT 2023 AND VI 37 AND IP 3
Results: 11
Review and Update of Active and Passive Immunization Against Respiratory Syncytial Virus.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 295, doi. 10.1007/s40259-023-00596-4
- By:
- Publication type:
- Article
Modification of Extracellular Vesicle Surfaces: An Approach for Targeted Drug Delivery.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 353, doi. 10.1007/s40259-023-00595-5
- By:
- Publication type:
- Article
Advanced Delivery Strategies for Immunotherapy in Type I Diabetes Mellitus.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 331, doi. 10.1007/s40259-023-00594-6
- By:
- Publication type:
- Article
Characterization of a HIR-Fab-IDS, Novel Iduronate 2-Sulfatase Fusion Protein for the Treatment of Neuropathic Mucopolysaccharidosis Type II (Hunter Syndrome).
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 375, doi. 10.1007/s40259-023-00590-w
- By:
- Publication type:
- Article
Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 409, doi. 10.1007/s40259-023-00589-3
- By:
- Publication type:
- Article
Correction to: Understanding US Physician and Pharmacist Attitudes Toward Biosimilar Products: A Qualitative Study.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Targeting IL-36 in Inflammatory Skin Diseases.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 279, doi. 10.1007/s40259-023-00587-5
- By:
- Publication type:
- Article
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 421, doi. 10.1007/s40259-023-00586-6
- By:
- Publication type:
- Article
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 311, doi. 10.1007/s40259-023-00585-7
- By:
- Publication type:
- Article
Severe Hypersensitivity Reactions at Biosimilar versus Originator Rituximab Treatment Initiation, Switch and Over Time: A Cohort Study on the French National Health Data System.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 397, doi. 10.1007/s40259-023-00584-8
- By:
- Publication type:
- Article
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
- Published in:
- BioDrugs, 2023, v. 37, n. 3, p. 433, doi. 10.1007/s40259-023-00582-w
- By:
- Publication type:
- Article